852471-15-9

Basic information

• Product Name: 1-acetyl-1,2-dihydro-3H-pyrazol-3-one
• Synonyms: 1-acetyl-1,2-dihydro-3H-pyrazol-3-one
• CAS NO: 852471-15-9
• Molecular Weight: 126.115
• Mol File: 852471-15-9.mol
• Article Data: 25

Chemical Properties

• CAS DataBase Reference: 1-acetyl-1,2-dihydro-3H-pyrazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-acetyl-1,2-dihydro-3H-pyrazol-3-one(852471-15-9)
• EPA Substance Registry System: 1-acetyl-1,2-dihydro-3H-pyrazol-3-one(852471-15-9)

Safety Data

• Hazardous Substances Data: 852471-15-9(Hazardous Substances Data)

Usage

Physical state

Colorless or pale yellow liquid

Odor

Pungent

Solubility

Soluble in water and various organic solvents

Usage

Building block in the synthesis of other organic compounds

Usage

Solvent in various industrial processes

Role

Ligand in coordination chemistry, forming complexes with metal ions

Potential applications

Pharmaceuticals

Potential applications

Agrochemicals

Upstream product

• 108-24-7 acetic anhydride 
• 137-45-1 3-hydroxy pyrazole 
• 5788-17-0 methyl (2E)-3-methoxy-2-propenoate 
• 137-45-1 1,2-dihydropyrazol-3-one 
• 60456-93-1 5-hydroxy-pyrazole 

Downstream Products

• 215610-30-3 3-methoxy-1H-pyrazole 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY

The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process. (I)